which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

which is currently under FDA review. Approval for a monthly IV dose of Leqembi is also being sought. The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the approval, saying it would ...

A chemist a UAlbany and his son are looking to make a major breakthrough in the world of Alzheimer's prevention. They believe ...

Hoping to skirt the slow pace of new drug development, researchers are leaning on AI to uncover fresh uses for known ...

If the European Medicines Agency takes an overly cautious approach to selecting specialists to advise on new medicines, ...

According to the FDA, the drug is approved for people with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and those with the mild dementia stage of Alzheimer’s ...

The new Alzheimer’s drug Kinsula is offering hope for patients by slowing down the progression of the disease. Neurologist Dr. Mauricio Concha administered the drug ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, faces hurdles with respect to reimbursement and diagnostic uncertainties, diagnostic test requirements and the need for regular brain scans, CNBC ...

For Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease, these new drugs mark an ...

"There are currently no approved treatments for DLB, so doctors often use drugs for Alzheimer's disease, such as ...

Laboratory mice with cognitive issues including Alzheimer's disease showed improved memory skills within a couple of weeks of ...

A study found that new monoclonal antibody drugs for Alzheimer's may slow cognitive impairment through boosting levels of a specific protein in the brain.